BUZZ-Street View: FDA nod for Vertex's oral non-opioid painkiller 'the start of something big'
The U.S. Food and Drug Administration on Thursday approved Vertex Pharmaceuticals' VRTX.O drug, branded as Journavx, to treat acute pain, offering a first-of-its-kind alternative to addictive opioid painkillers that have fueled a national crisis
Shares up 7.39% to $470.8 premarket
PRICING NOT HIGH AS FEARED
BMO Capital Markets ("outperform", PT: $545) says approval in acute pain sets stage for VRTX's next leg of growth
Truist Securities ("buy", PT:$460) says price tag of Journavx is certainly higher than generic opioids, but not as high as feared
Leerink Partners ("outperform", PT: $542) notes the published drug labeling as a best-case scenario, pricing is roughly in line with its expectations
TD Cowen ("buy", PT: $525) suspects it may take time for Journavx's launch to gain momentum
Related Articles
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).
Why Sanae Takaichi Winning Japan’s Diet Election Led to a Surge in Japanese Stock Indices？
TradingKey - Reports indicate that the ruling coalition led by Japanese Prime Minister Sanae Takaichi has secured a single-party majority in the parliamentary elections held on Sunday (February 8). Following the news, the yen weakened slightly, while the Nikkei Index surpassed 57,000 for the first t
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 market
